EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

PB006: A Natalizumab Biosimilar

Matt Shirley

Clinical Drug Investigation · 2024

DOI: 10.1007/s40261-024-01360-4 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Drug Investigation, 2024. Verfasst von Matt Shirley. Beteiligte Einrichtung: Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand. demail@springer.com. Hauptthemen laut MEDLINE: Natalizumab, Biosimilar Pharmaceuticals, Multiple Sclerosis, Relapsing-Remitting. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 5 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PB006 (Tyruko®) is the first biosimilar of the reference monoclonal anti-α4-integrin antibody natalizumab. It is approved for use in the same indications for which reference natalizumab is approved, as a single disease-modifying therapy in adults with highly active relapsing-remitting multiple sclerosis (RRMS). PB006 has similar physicochemical and pharmacodynamic properties to those of reference natalizumab, and the pharmacokinetic similarity of the agents has been demonstrated in a study in healthy subjects. PB006 demonstrated clinical efficacy similar to that of reference natalizumab in patients with RRMS, and was generally well tolerated in this population. The tolerability, safety and immunogenicity profiles of PB006 were similar to those of reference natalizumab, and switching from reference natalizumab to PB006 appeared to have no impact on tolerability or immunogenicity. The role of reference natalizumab in the management of RRMS is well established and PB006 provides an effective biosimilar alternative for patients requiring natalizumab therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NatalizumabBiosimilar PharmaceuticalsMultiple Sclerosis, Relapsing-RemittingHumans

Substanzen

NatalizumabBiosimilar Pharmaceuticals

Autor:innen und Institutionen

  • Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand. demail@springer.com.

Zitieren

APA

Shirley, M. (2024). PB006: A Natalizumab Biosimilar. Clinical Drug Investigation. https://doi.org/10.1007/s40261-024-01360-4

Vancouver

Shirley M. PB006: A Natalizumab Biosimilar. Clinical Drug Investigation. 2024. doi:10.1007/s40261-024-01360-4

BibTeX
@article{Shirley2024,
  author = {Shirley, Matt},
  title = {PB006: A Natalizumab Biosimilar},
  journal = {Clinical Drug Investigation},
  year = {2024},
  doi = {10.1007/s40261-024-01360-4}
}
Kostenlos starten →